Loading
A phase 1/2 trial of RP1, intra-tumoral injection, oncolytic virus in merkel cell carcinoma, basal cell carcinoma and cutaneous squamous cell carcinoma, run by Replimune, Inc., active and no longer recruiting.
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies is a phase 1/2 interventional study registered as NCT04349436 by Replimune, Inc., with 69 participants enrolled, started 2020-05-15 and due to reach its primary completion in 2029-07. Interventions recorded: RP1, intra-tumoral injection, oncolytic virus.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma and the tag pipeline.
Shares Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma and the tag pipeline.
Shares Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma and the tag pipeline.
Shares Cutaneous squamous cell carcinoma, Basal cell carcinoma and the tag pipeline.
Shares Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma and the tag pipeline.
Shares Replimune and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Merkel cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/